Study to Compare Milk Protein Isolate (MPI) With Caseinate in Terms of Protein Utilization

Sponsor
University College Cork (Other)
Overall Status
Completed
CT.gov ID
NCT01599988
Collaborator
(none)
24
1
2
6
4

Study Details

Study Description

Brief Summary

The Clinical Research Ethics Committee, Cork comprises of faculty representatives, external representatives, legal representatives and appropriate individuals and ex-officio administrative members with needed expertise. Ethics Committee members, including the Chair, are appointed by the Head of College, University College Cork, Medical School.

The Ethics Committee meets once a month.

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: Caseinate
  • Dietary Supplement: Milk Protein Isolate
Phase 2/Phase 3

Study Design

Study Type:
Interventional
Actual Enrollment :
24 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Basic Science
Official Title:
A Randomised, Double-blinded Study to Compare Milk Protein Isolate (MPI)With Caseinate in Terms of Protein Utilization in Healthy Elderly Subjects
Study Start Date :
Oct 1, 2011
Actual Primary Completion Date :
Mar 1, 2012
Actual Study Completion Date :
Apr 1, 2012

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Milk protein isolate

The test meal is a vanilla flavoured enteral drink, containing 1.5kcal/ml, 21% CHO, 6% protein and 5% fat. The 6% protein in this test meal is Milk Protein Isolate.

Dietary Supplement: Milk Protein Isolate
The test meal is a vanilla flavoured enteral drink, containing 1.5kcal/ml, 21% CHO, 6% protein and 5% fat. The 6% protein in this test meal is Milk Protein Isolate.

Active Comparator: Caseinate

The test meal is a vanilla flavoured enteral drink, containing 1.5kcal/ml, 21% CHO, 6% protein and 5% fat. The 6% protein in this test meal is Caseinate.

Dietary Supplement: Caseinate
The test meal is a vanilla flavoured enteral drink, containing 1.5kcal/ml, 21% CHO, 6% protein and 5% fat. The 6% protein in this test meal is Caseinate

Outcome Measures

Primary Outcome Measures

  1. Protein utilization [Up to 8 hours]

Secondary Outcome Measures

  1. Blood glucose concentrations [Up to 8 hours]

  2. Plasma insulin levels [Up to 8 hours]

  3. Serum triglycerides [Up to 8 hours]

Eligibility Criteria

Criteria

Ages Eligible for Study:
65 Years to 75 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:

To be considered eligible for enrolment into the study, subjects must;

  1. Be able to give written informed consent.

  2. Be between 65 and 75 years of age.

  3. Be in generally good health as determined by the investigator.

  4. Have no evidence of gastrointestinal disease or of a functional gastrointestinal disorder as determined by the Bowel Disease Questionnaire.

  5. Have a stable body weight over the past 3-months.

  6. Have a Body Mass Index (BMI) greater than 22, for males and 20 for females and less than 30.

  7. Have a satisfactory nutritional status.

Exclusion Criteria:

Subjects will be excluded from the study if they meet any of the below criteria;

  1. Are less than 65 and greater than 75 years of age.

  2. Have evidence of gastrointestinal disease or other functional gastrointestinal disorder as determined by the Bowel Disease Questionnaire.

  3. Have a significant acute or chronic coexisting illness (cardiovascular, gastrointestinal, endocrinological, immunological, metabolic or any condition which contraindicates, in the investigators judgement, entry to the study).

  4. Having a condition or taking a medication that the investigator believes would interfere with the objectives of the study, pose a safety risk or confound the interpretation of the study results; to include anti-inflammatory drugs, corticosteroids, laxatives, enemas, antibiotics (within 1 month), anti-coagulants, and over-the counter non-steroidal analgesics. Subjects should have a wash-out period of two-weeks.

  5. Be a smoker.

  6. Consume more than the recommended alcohol guidelines i.e. 3-4 alcohol units a day for a man and for a woman 2-3 units a day.

  7. Suffer from psychiatric disease

  8. Prior gastrointestinal surgery (apart from appendicectomy and hernia repair) or recent unexplained bleeding.

  9. Have dietary habits (slimming or vegetarian diet) which could interfere with the assessment of the study product.

  10. Individuals who, in the opinion of the investigator, are considered to be poor attendees or unlikely for any reason to be able to comply with the trial.

  11. Subjects may not be receiving treatment involving experimental drugs.

  12. If the subject has been in a recent experimental trial, these must have been completed not less than 30 days prior to this study.

  13. Have a malignant disease or any concomitant end-stage organ disease

Contacts and Locations

Locations

Site City State Country Postal Code
1 University College Cork Cork Ireland

Sponsors and Collaborators

  • University College Cork

Investigators

  • Principal Investigator: Fergus Shanahan, MD, BSc, University College Cork

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Andrea Doolan, Human Studies Manager, University College Cork
ClinicalTrials.gov Identifier:
NCT01599988
Other Study ID Numbers:
  • APC032
First Posted:
May 16, 2012
Last Update Posted:
Jan 16, 2013
Last Verified:
Jan 1, 2013
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 16, 2013